This educational initiative will provide rheumatology clinicians with an evidence-based update on the evolving role of B-cell–targeted and dual-mechanism therapies in the management of Sjögren’s disease, with a focus on improving disease recognition, diagnosis, and long-term outcomes. The expert faculty, Dr. Sara McCoy, will review the latest clinical trial data for emerging therapies, including novel B-cell depleting and BAFF-R–inhibiting agents, while exploring their potential to move treatment beyond symptomatic control toward meaningful disease modification and improved patient quality of life. Through case discussion and evidence-based analysis, participants will gain practical strategies for individualized care, shared decision-making, and multidisciplinary management of the systemic manifestations and burdens of Sjögren’s disease.
Rheumatologists, advanced practice providers who work with these specialists, and other healthcare providers who contribute to the management of patients with Sjögren’s disease
Discuss the updated understanding of pathophysiology, screening, diagnosis, and therapeutic targets of Sjögren’s disease
Analyze the most up to date evidence for B-cell depleting therapies, including that of a novel dual mechanism B-cell depletor and BAFF-R inhibitor, to improve the management of patients with Sjögren’s disease
Review the potential role of DMT with novel B-cell depleting and dual mechanism therapies to improve patient quality of life and reduce disease burden in Sjögren’s disease
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Sara McCoy, MD, PhD | Consultant/Advisor: Amgen; argenx; Artiva Biotherapeutics, Inc.; Johnson & Johnson; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Veloxis Pharmaceuticals, Inc; Visterra, Inc.
Speaker’s Bureau: Amgen; Johnson & Johnson; Novartis Pharmaceuticals Corporation Founder: Quench Therapeutics |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of Continuing Pharmacy Education Credit (UAN #JA4008190-0000-26-013-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
